Literature DB >> 12919154

Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans.

Roberta Giordano1, Silvia Grottoli, PierClaudio Brossa, Micaela Pellegrino, Silvia Destefanis, Fabio Lanfranco, Laura Gianotti, Ezio Ghigo, Emanuela Arvat.   

Abstract

OBJECTIVE: Alprazolam (ALP), a benzodiazepine-activating GABAergic receptor, possesses clear centrally mediated inhibitory effects on ACTH and cortisol secretion that could reflect an inhibitory influence on CRH- and/or AVP-secreting neurones. An inhibitory effect of ALP on catecholamine release has also been shown while its effect on GH secretion is unclear. To further clarify the neuroendocrine actions of ALP, we studied the ALP effects on the neurohormonal responses to hypoglycaemia in a group of normal subjects.
DESIGN: In eight normal subjects [four women and four men, 22-34 years old, body mass index (BMI) 20-25 kg/m2] the ACTH, cortisol, GH, adrenaline (A) and noradrenaline (NA) responses to insulin-induced hypoglycaemia [ITT, 0.1 UI/kg regular insulin intravenously (i.v.) at 0 min] preceded by placebo or ALP (0.02 mg/kg orally at -90 min) were studied in two sessions at least 10 days apart. MEASUREMENTS: Blood samples were taken basely at -90 and 0 min and every 15 min up to +120 min. ACTH, cortisol, GH, A and NA level were assayed at each time point in both sessions.
RESULTS: All subjects experienced hypoglycaemia (plasma glucose levels below 2.2 mmol/l). After placebo ITT induced clear-cut increases in ACTH (peak vs. baseline, mean +/- SEM: 27.9 +/- 3.9 vs. 7.1 +/- 1.5 pmol/l), cortisol (438.1 +/- 32.0 vs. 237.7 +/- 19.3 nmol/l) and GH (38.1 +/- 9.7 vs. 5.7 +/- 2.0 micro g/l) levels (P < 0.05). Marked increase in A (6627.2 +/- 116.7 vs. 263.7 +/- 71.4 pmol/l) and NA (3.8 +/- 1.5 vs. 1.6 +/- 1.0 nmol/l) levels were also recorded (P < 0.05). Pretreatment with ALP significantly inhibited the ACTH peak response to ITT (17.8 +/- 5.0 pmol/l, P < 0.05), while the cortisol response showed a non significant reduction (342.1 +/- 38.7 nmol/l). ALP also significantly reduced the GH (21.7 +/- 4.7 micro g/l, P < 0.02) and A (3828.0 +/- 1400.7 pmol/l, P < 0.02) responses to ITT. On the contrary, ALP lowered basal NA levels (P < 0.05) but did not significantly affect its response to ITT (2.2 +/- 1.2 nmol/l). Glucose changes induced by ITT were not modified by ALP.
CONCLUSIONS: This study shows that GABAergic activation by alprazolam significantly inhibits the neuroendocrine and adrenomedullary responses to hypoglycaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919154     DOI: 10.1046/j.1365-2265.2003.01847.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Naloxone decreases the inhibitory effect of alprazolam on the release of adrenocorticotropin/cortisol induced by physical exercise in man.

Authors:  Vittorio Coiro; Riccardo Volpi; Amos Casti; Maria Ludovica Maffei; Adriano Stella; Elio Volta; Paolo Chiodera
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Sex differences in diazepam effects and parvalbumin-positive GABA neurons in trait anxiety Long Evans rats.

Authors:  Rebecca Ravenelle; Nichole M Neugebauer; Timothy Niedzielak; S Tiffany Donaldson
Journal:  Behav Brain Res       Date:  2014-05-06       Impact factor: 3.332

Review 3.  Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Endocr Regul       Date:  2008-09

4.  Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia.

Authors:  Yen-Yue Lin; Chin-Wang Hsu; Wayne Huey-Herng Sheu; Shi-Jye Chu; Chin-Pyng Wu; Shih-Hung Tsai
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

5.  Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome.

Authors:  Roberta Giordano; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Andreea Picu; Clizia Zichi; Beatrice Fussotto; Maria Manzo; Giulio Mengozzi; Ezio Ghigo; Emanuela Arvat
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

6.  Increased GABAergic tone in the ventromedial hypothalamus contributes to suppression of counterregulatory responses after antecedent hypoglycemia.

Authors:  Owen Chan; Haiying Cheng; Raimund Herzog; Daniel Czyzyk; Wanling Zhu; Ajin Wang; Rory J McCrimmon; Margretta R Seashore; Robert S Sherwin
Journal:  Diabetes       Date:  2008-03-28       Impact factor: 9.461

7.  Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats.

Authors:  Owen Chan; Sachin Paranjape; Daniel Czyzyk; Adam Horblitt; Wanling Zhu; Yuyan Ding; Xiaoning Fan; Margretta Seashore; Robert Sherwin
Journal:  Diabetes       Date:  2011-03-16       Impact factor: 9.461

8.  Effects of Antecedent GABA A Receptor Activation on Counterregulatory Responses to Exercise in Healthy Man.

Authors:  Maka S Hedrington; Donna B Tate; Lisa M Younk; Stephen N Davis
Journal:  Diabetes       Date:  2015-04-21       Impact factor: 9.461

9.  Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans.

Authors:  Maka S Hedrington; Stephnie Farmerie; Andrew C Ertl; Zhihui Wang; Donna B Tate; Stephen N Davis
Journal:  Diabetes       Date:  2010-01-19       Impact factor: 9.461

10.  Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans.

Authors:  Ameera X Patel; Sam R Miller; Pradeep J Nathan; Ponmani Kanakaraj; Antonella Napolitano; Philip Lawrence; Annelize Koch; Edward T Bullmore
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.